Pacira BioSciences, Inc. (PCRX)
USD 25.75
(2.18%)
USD 25.75
(2.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 586.04 Million USD | -23.23% |
| 2022 | 763.39 Million USD | -32.37% |
| 2021 | 1.12 Billion USD | 108.61% |
| 2020 | 541.12 Million USD | 53.77% |
| 2019 | 351.91 Million USD | 20.96% |
| 2018 | 290.93 Million USD | 5.22% |
| 2017 | 276.49 Million USD | 154.28% |
| 2016 | 108.73 Million USD | 2.65% |
| 2015 | 105.92 Million USD | 2.74% |
| 2014 | 103.1 Million USD | 4.18% |
| 2013 | 98.96 Million USD | 279.92% |
| 2012 | 26.04 Million USD | -8.06% |
| 2011 | 28.33 Million USD | 13.1% |
| 2010 | 25.05 Million USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 581.77 Million USD | -0.73% |
| 2024 Q2 | 648.59 Million USD | 11.49% |
| 2023 Q1 | 625.16 Million USD | -18.11% |
| 2023 Q3 | 590.29 Million USD | -4.9% |
| 2023 Q2 | 620.71 Million USD | -0.71% |
| 2023 FY | 586.04 Million USD | -23.23% |
| 2023 Q4 | 586.04 Million USD | -0.72% |
| 2022 Q3 | 821.63 Million USD | -1.17% |
| 2022 Q4 | 763.39 Million USD | -7.09% |
| 2022 FY | 763.39 Million USD | -32.37% |
| 2022 Q1 | 1 Billion USD | -11.31% |
| 2022 Q2 | 831.36 Million USD | -16.96% |
| 2021 Q3 | 554.56 Million USD | 0.96% |
| 2021 FY | 1.12 Billion USD | 108.61% |
| 2021 Q1 | 544.15 Million USD | 0.56% |
| 2021 Q4 | 1.12 Billion USD | 103.56% |
| 2021 Q2 | 549.26 Million USD | 0.94% |
| 2020 Q1 | 354.23 Million USD | 0.66% |
| 2020 Q2 | 395.69 Million USD | 11.7% |
| 2020 Q3 | 536.36 Million USD | 35.55% |
| 2020 Q4 | 541.12 Million USD | 0.89% |
| 2020 FY | 541.12 Million USD | 53.77% |
| 2019 Q3 | 346 Million USD | 0.76% |
| 2019 Q4 | 351.91 Million USD | 1.71% |
| 2019 Q2 | 343.39 Million USD | 4.3% |
| 2019 Q1 | 329.23 Million USD | 13.17% |
| 2019 FY | 351.91 Million USD | 20.96% |
| 2018 Q4 | 290.93 Million USD | 1.29% |
| 2018 FY | 290.93 Million USD | 5.22% |
| 2018 Q3 | 287.22 Million USD | 1.28% |
| 2018 Q2 | 283.58 Million USD | 1.28% |
| 2018 Q1 | 280.01 Million USD | 1.27% |
| 2017 Q2 | 269.64 Million USD | 1.09% |
| 2017 Q1 | 266.75 Million USD | 145.32% |
| 2017 Q3 | 273.04 Million USD | 1.26% |
| 2017 FY | 276.49 Million USD | 154.28% |
| 2017 Q4 | 276.49 Million USD | 1.27% |
| 2016 FY | 108.73 Million USD | 2.65% |
| 2016 Q1 | 105.21 Million USD | -0.67% |
| 2016 Q3 | 107.56 Million USD | 1.1% |
| 2016 Q4 | 108.73 Million USD | 1.09% |
| 2016 Q2 | 106.38 Million USD | 1.11% |
| 2015 Q1 | 104.13 Million USD | 1.0% |
| 2015 Q4 | 105.92 Million USD | 0.97% |
| 2015 FY | 105.92 Million USD | 2.74% |
| 2015 Q2 | 103.88 Million USD | -0.24% |
| 2015 Q3 | 104.9 Million USD | 0.98% |
| 2014 Q2 | 101.03 Million USD | 1.04% |
| 2014 Q4 | 103.1 Million USD | 1.01% |
| 2014 Q1 | 99.99 Million USD | 1.05% |
| 2014 FY | 103.1 Million USD | 4.18% |
| 2014 Q3 | 102.06 Million USD | 1.02% |
| 2013 Q4 | 98.96 Million USD | 1.06% |
| 2013 FY | 98.96 Million USD | 279.92% |
| 2013 Q3 | 97.92 Million USD | 1.07% |
| 2013 Q2 | 96.89 Million USD | 1.08% |
| 2013 Q1 | 95.85 Million USD | 268.0% |
| 2012 Q4 | 26.04 Million USD | -2.25% |
| 2012 Q1 | 27.65 Million USD | -2.38% |
| 2012 FY | 26.04 Million USD | -8.06% |
| 2012 Q2 | 24.67 Million USD | -10.81% |
| 2012 Q3 | 26.64 Million USD | 8.02% |
| 2011 Q4 | 28.33 Million USD | 11.22% |
| 2011 Q2 | 28.9 Million USD | 14.99% |
| 2011 Q1 | 25.13 Million USD | 0.35% |
| 2011 Q3 | 25.47 Million USD | -11.87% |
| 2011 FY | 28.33 Million USD | 13.1% |
| 2010 Q3 | 55.54 Million USD | 887.5% |
| 2010 FY | 25.05 Million USD | 0.0% |
| 2010 Q4 | 25.05 Million USD | -54.9% |
| 2010 Q2 | 5.62 Million USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -3359.936% |
| PainReform Ltd. | 86 Thousand USD | -681346.512% |
| Alvotech | 1.07 Billion USD | 45.508% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 13.086% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -85.852% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -493.03% |
| Journey Medical Corporation | 17.73 Million USD | -3205.381% |
| Dynavax Technologies Corporation | 256.91 Million USD | -128.109% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -8.337% |
| Bright Green Corporation | 1.85 Million USD | -31547.553% |
| Embecta Corp. | 1.63 Billion USD | 64.233% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -89004.386% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -89004.386% |
| SCYNEXIS, Inc. | 15.08 Million USD | -3786.233% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -6980.741% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -22036.127% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1824.105% |
| Safety Shot Inc | 1.54 Million USD | -37734.334% |
| Procaps Group, S.A. | 285.93 Million USD | -104.957% |
| Cosmos Health Inc. | 12.42 Million USD | -4617.05% |
| Theratechnologies Inc. | 58.96 Million USD | -893.834% |
| Harrow Health, Inc. | 190.5 Million USD | -207.631% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -96288.816% |
| Biofrontera Inc. | 5.39 Million USD | -10754.677% |
| DURECT Corporation | 20.74 Million USD | -2724.853% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1311.236% |
| Cronos Group Inc. | 2.53 Million USD | -22973.162% |
| OptiNose, Inc. | 131.74 Million USD | -344.819% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 18.097% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1513.424% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -49860.87% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -391.026% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -3080.099% |
| Radius Health, Inc. | 365.31 Million USD | -60.422% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -10589.443% |
| ProPhase Labs, Inc. | 21.38 Million USD | -2641.085% |
| Phibro Animal Health Corporation | 525.45 Million USD | -11.53% |
| Procaps Group S.A. | 285.93 Million USD | -104.957% |
| TherapeuticsMD, Inc. | 8 Million USD | -7220.974% |
| Viatris Inc. | 18.12 Billion USD | 96.766% |
| Rockwell Medical, Inc. | 13.43 Million USD | -4260.771% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -3773.647% |
| SIGA Technologies, Inc. | 1.46 Million USD | -39930.082% |
| Tilray Brands, Inc. | 387.31 Million USD | -51.309% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -349.558% |
| Shineco, Inc. | 29.65 Million USD | -1876.11% |
| PetIQ, Inc. | 468.3 Million USD | -25.142% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -979791.986% |
| Incannex Healthcare Limited | 373 Thousand USD | -157016.354% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -36.798% |
| Alimera Sciences, Inc. | 67.39 Million USD | -769.514% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1332.45% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -53779.492% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -27980.69% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -56625.921% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1556.24% |
| Hempacco Co., Inc. | 13.72 Million USD | -4170.056% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 45.508% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -838.181% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 5.009% |
| Currenc Group, Inc. | 31.94 Million USD | -1734.619% |
| Kamada Ltd. | 8.74 Million USD | -6598.421% |
| Indivior PLC | 281.6 Million USD | -108.111% |
| Evoke Pharma, Inc. | 5 Million USD | -11620.88% |
| Flora Growth Corp. | 3.67 Million USD | -15859.804% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -56625.921% |
| Evolus, Inc. | 126.54 Million USD | -363.107% |
| HUTCHMED (China) Limited | 86.13 Million USD | -580.41% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 6.029% |
| Akanda Corp. | 3.99 Million USD | -14555.53% |